The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Osinov I.K.

Burdenko Neurosurgical Center;
Moscow Center Gamma Knife

Kostjuchenko V.V.

Business Center of Neurosurgery

Kobyakov G.L.

Burdenko Neurosurgical Center

Belyashova A.S.

Burdenko Neurosurgical Center

Batalov A.I.

Burdenko Neurosurgical Center

Antipina N.A.

Burdenko Neurosurgical Center

Golanov A.V.

Burdenko Neurosurgical Center

Radiosurgery for recurrent glioblastoma

Authors:

Osinov I.K., Kostjuchenko V.V., Kobyakov G.L., Belyashova A.S., Batalov A.I., Antipina N.A., Golanov A.V.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2021;85(6): 76‑82

DOI: 10.17116/neiro20218506176

Read: 6125 times

Download PDF (RU)
Download PDF
Contact the author
Table of contents

RADIOSURGERY FOR RECURRENT GLIOBLASTOMA
RADIOSURGERY FOR RECURRENT GLIOBLASTOMA

To cite this article:

Osinov IK, Kostjuchenko VV, Kobyakov GL, Belyashova AS, Batalov AI, Antipina NA, Golanov AV. Radiosurgery for recurrent glioblastoma. Burdenko's Journal of Neurosurgery. 2021;85(6):76‑82. (In Russ., In Engl.)
https://doi.org/10.17116/neiro20218506176

Подписка 2025 Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко (Burdenko's Journal of Neurosurgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Radiosurgery for neurosurgical diseases (by the 20th anni­versary of neuroradiosurgery in Russia). Burdenko's Journal of Neurosurgery. 2025;(6):7-15
Post-radiation choroidal mela­noma pathomorphosis asse­ssment in clinical practice. Russian Journal of Archive of Pathology. 2025;(3):33-39
Inva­sive Treatment of Recu­rrent Vari­cose Veins in Patients with Femo­ral Vein Inco­mpetence. Journal of Venous Diso­rders. 2025;(3):156-163
Abstract:

BACKGROUND

Despite the combined treatment in accordance with modern standards, recurrent glioblastoma usually occurs within several months after resection and causes low relapse-free and overall survival. One of the most effective methods for malignant glioma progression is repeated radiotherapy. Indications for this approach have expanded after introduction of stereotactic irradiation into routine clinical practice.

OBJECTIVE

To evaluate the results of radiosurgery in patients with recurrent glioblastoma and to identify the factors determining its effectiveness.

MATERIAL AND METHODS

Radiosurgery has been carried out in 168 patients with relapses of glioblastoma between 2005 and 2021. This study enrolled 88 patients with 180 foci of local and distant progression. Mean age of patients was 42.8±2.1 years (range 4—73). Mean period between diagnosis and repeated irradiation was 12.7 months. Mean volume of focus was 2.4 cm3, mean dose — 20 Gy. Median follow-up period after radiosurgery was 11.2 months.

RESULTS

Repeated irradiation with correction of systemic therapy improved progression-free survival and overall survival with insignificant radiation-induced toxicity. Annual overall survival was 62.2%, median of overall survival after radiosurgery — 15.1 months. Significant factors of local control were marginal dose of at least 18 Gy and distant relapse. Median of progression-free survival in the group of distant progression of glioblastoma was only 3.6 months vs. 9.1 months in patients with local recurrence.

CONCLUSION

Repeated irradiation in radiosurgery mode with a dose of 18 Gy and higher is an effective option for local treatment increasing progression-free and overall survival in patients with progression of glioblastoma.

Keywords:

glioblastomas
relapses
progression
radiosurgery
Gamma Knife

Authors:

Osinov I.K.

Burdenko Neurosurgical Center;
Moscow Center Gamma Knife

Kostjuchenko V.V.

Business Center of Neurosurgery

Kobyakov G.L.

Burdenko Neurosurgical Center

Belyashova A.S.

Burdenko Neurosurgical Center

Batalov A.I.

Burdenko Neurosurgical Center

Antipina N.A.

Burdenko Neurosurgical Center

Golanov A.V.

Burdenko Neurosurgical Center

Received:

03.10.2021

Accepted:

08.10.2021

Close metadata

References:

  1. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro-Oncology. 2020;22(12 Suppl 2):iv1-iv96. https://doi.org10.1093/neuonc/noaa200
  2. Gzell C, Back M, Wheeler H, Bailey D, Foote M. Radiotherapy in Glioblastoma: the Past, the Present and the Future. Clinical Oncology. 2017;29(1):15-25.  https://doi.org10.1016/j.clon.2016.09.015
  3. Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn J-C, Tsang J, Verhaak RGW, Deimling A von, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology. 2020;22(8):1073-1113. https://doi.org10.1093/neuonc/noaa106
  4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine. 2005;352(10):987-996.  https://doi.org10.1056/NEJMoa043330
  5. Cabrera AR, Kirkpatrick JP, Fiveash JB, Shih HA, Koay EJ, Lutz S, Petit J, Chao ST, Brown PD, Vogelbaum M, Reardon DA, Chakravarti A, Wen PY, Chang E. Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Practical Radiation Oncology. 2016;6(4):217-225.  https://doi.org10.1016/j.prro.2016.03.007
  6. Corso CD, Bindra RS, Mehta MP. The role of radiation in treating glioblastoma: here to stay. Journal of Neuro-Oncology. 2017;134(3):479-485.  https://doi.org10.1007/s11060-016-2348-x
  7. Schäfer N, Gielen GH, Rauschenbach L, Kebir S, Till A, Reinartz R, Simon M, Niehusmann P, Kleinschnitz C, Herrlinger U, Pietsch T, Scheffler B, Glas M. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors. Journal of Translational Medicine. 2019;17(1):96.  https://doi.org10.1186/s12967-019-1846-y
  8. Seystahl K, Wick W, Weller M. Therapeutic options in recurrent glioblastoma — An update. Critical Reviews in Oncology/Hematology. 2016;99:389-408.  https://doi.org10.1016/j.critrevonc.2016.01.018
  9. Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, Deimling A von, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ. Lomustine and Bevacizumab in Progressive Glioblastoma. The New England Journal of Medicine. 2017;377(20):1954-1963. https://doi.org10.1056/NEJMoa1707358
  10. Lewitzki V, Klement RJ, Kosmala R, Lisowski D, Flentje M, Polat B. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma. Radiation Oncology. 2019;14(1):227.  https://doi.org10.1186/s13014-019-1427-5
  11. Shah JL, Li G, Shaffer JL, Azoulay MI, Gibbs IC, Nagpal S, Soltys SG. Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma. Neurosurgery. 2018;82(1):24-34.  https://doi.org10.1093/neuros/nyx115
  12. Skeie BS, Enger PØ, Brøgger J, Ganz JC, Thorsen F, Heggdal JI, Pedersen P-H. γ knife surgery versus reoperation for recurrent glioblastoma multiforme. World Neurosurgery. 2012;78(6):658-669.  https://doi.org10.1016/j.wneu.2012.03.024
  13. Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. International Journal of Radiation Oncology, Biology, Physics. 2012;82(5):2018-2024. https://doi.org10.1016/j.ijrobp.2010.12.074
  14. Clarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, Lassman AB, Chan TA, Yamada J, DeAngelis L, Ballangrud A, Young R, Panageas KS, Beal K, Omuro A. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy with Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. International Journal of Radiation Oncology, Biology, Physics. 2017;99(4):797-804.  https://doi.org10.1016/j.ijrobp.2017.06.2466
  15. Straube C, Kessel KA, Zimmer C, Schmidt-Graf F, Schlegel J, Gempt J, Meyer B, Combs SE. A Second Course of Radiotherapy in Patients with Recurrent Malignant Gliomas: Clinical Data on Re-irradiation, Prognostic Factors, and Usefulness of Digital Biomarkers. Current Treatment Options in Oncology. 2019;20(9):71.  https://doi.org10.1007/s11864-019-0673-y
  16. Ryu S, Buatti JM, Morris A, Kalkanis SN, Ryken TC, Olson JJ; AANS/CNS Joint Guidelines Committee. The role of radiotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology. 2014;118(3):489-499.  https://doi.org10.1007/s11060-013-1337-6
  17. Kazmi F, Soon YY, Leong YH, Koh WY, Vellayappan B. Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis. Journal of Neuro-Oncology. 2019;142(1):79-90.  https://doi.org10.1007/s11060-018-03064-0
  18. Scoccianti S, Francolini G, Carta GA, Greto D, Detti B, Simontacchi G, Visani L, Baki M, Poggesi L, Bonomo P, Mangoni M, Desideri I, Pallotta S, Livi L. Re-irradiation as salvage treatment in recurrent glioblastoma: A comprehensive literature review to provide practical answers to frequently asked questions. Critical Reviews in Oncology/Hematology. 2018;126:80-91.  https://doi.org10.1016/j.critrevonc.2018.03.024
  19. Kondziolka D, Flickinger JC, Bissonette DJ, Bozik M, Lunsford LD. Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery. 1997;41(4):776-783; discussion 783-785.  https://doi.org10.1097/00006123-199710000-00004
  20. Combs SE, Niyazi M, Adeberg S, Bougatf N, Kaul D, Fleischmann DF, Gruen A, Fokas E, Rödel CM, Eckert F, Paulsen F, Oehlke O, Grosu A-L, Seidlitz A, Lattermann A, Krause M, Baumann M, Guberina M, Stuschke M, Budach V, Belka C, Debus J, Kessel KA. Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK). Cancer Medicine. 2018;7(5):1742-1749. https://doi.org10.1002/cam4.1425
  21. Shanker M, Chua B, Bettington C, Foote MC, Pinkham MB. Re-irradiation for recurrent high-grade gliomas: a systematic review and analysis of treatment technique with respect to survival and risk of radionecrosis. Neuro-Oncology Practice. 2019;6(2):144-155.  https://doi.org10.1093/nop/npy019
  22. Nejroradiohirurgiya na Gamma-nozhe. Pod red. Golanova A.V., Kostyuchenko V.V. M.: IP «T.A. Alekseeva»; 2018. (In Russ.).
  23. Møller S, Munck Af Rosenschöld P, Costa J, Law I, Poulsen HS, Engelholm SA, Engelholm S. Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial. Radiotherapy and Oncology. 2017;125(2):223-227.  https://doi.org10.1016/j.radonc.2017.09.039
  24. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, Farnan N. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. International Journal of Radiation Oncology, Biology,Physics. 2000;47(2):291-298.  https://doi.org10.1016/s0360-3016(99)00507-6
  25. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. International Journal of Radiation Oncology, Biology, Physics. 2009;75(1):156-163.  https://doi.org10.1016/j.ijrobp.2008.10.043
  26. Miwa K, Matsuo M, Ogawa S-i, Shinoda J, Yokoyama K, Yamada J, Yano H, Iwama T. Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy. Radiation Oncology. 2014;9:181.  https://doi.org10.1186/1748-717X-9-181
  27. Popp I, Bott S, Mix M, Oehlke O, Schimek-Jasch T, Nieder C, Nestle U, Bock M, Yuh WTC, Meyer PT, Weber WA, Urbach H, Mader I, Grosu A-L. Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. Radiotherapy and Oncology. 2019;130:121-131.  https://doi.org10.1016/j.radonc.2018.08.019
  28. Oehlke O, Mix M, Graf E, Schimek-Jasch T, Nestle U, Götz I, Schneider-Fuchs S, Weyerbrock A, Mader I, Baumert BG, Short SC, Meyer PT, Weber WA, Grosu A-L. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) — protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer. 2016;16(1):769.  https://doi.org10.1186/s12885-016-2806-z
  29. Mannino M, Chalmers AJ. Radioresistance of glioma stem cells: intrinsic characteristic or property of the “microenvironment-stem cell unit”? Molecular Oncology. 2011;5(4):374-386.  https://doi.org10.1016/j.molonc.2011.05.001
  30. Gupta K, Burns TC. Radiation-Induced Alterations in the Recurrent Glioblastoma Microenvironment: Therapeutic Implications. Frontiers in Oncology. 2018;8:503.  https://doi.org10.3389/fonc.2018.005032
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.